Sofinnova Partners crosses threshold in ABIVAX

On July 6, 2026, Sofinnova Partners announced by letter that it had fallen below the 5% threshold of voting rights in ABIVAX. This announcement concerns the Sofinnova Crossover I SLP fund, which Sofinnova Partners manages. As of July 1, 2026, Sofinnova held 2,877,494 shares, representing 4.92% of ABIVAX's voting rights, or 3.61% of the share capital.

This decrease resulted from two factors: an increase in the total number of shares and voting rights of ABIVAX, and the sale of shares on the market. ABIVAX, listed on Euronext Paris, had a share capital of 79,800,669 shares, representing 82,148,216 voting rights.